Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Nuolitong is a Traditional Chinese Medicine (TCM) granule formulation developed by Beijing Plantai Pharmaceutical Technology Development Co., Ltd. specifically for the treatment of tension-type headaches. The formulation is designed to promote blood circulation and resolve blood stasis, addressing the underlying 'stasis' believed to cause pain in TCM theory. Its primary botanical ingredients include *Ligusticum chuanxiong* and *Curcuma longa*. Pharmacologically, components like tetramethylpyrazine from *Ligusticum chuanxiong* are known to exert vasodilatory and anti-inflammatory effects, which contribute to the relief of headache symptoms. Nuolitong has been approved in China for the management of tension-type headaches and is used to reduce the frequency and intensity of headache episodes.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Nuolitong.